Ancor’s WellSpring Pharmaceutical acquires Bactine

Ancor Capital Partners is pleased to announce WellSpring Pharmaceutical Corporation, based in Sarasota, Fla., has acquired Bactine, ® the highly trusted first-aid antiseptic brand.

Ancor teamed with Sentinel Capital Partners to complete the transaction.

“We are very pleased to have completed the Bactine® acquisition just over a week after acquiring FDS, ®” said J. Randall Keene, Managing Partner at Ancor Capital Partners. “WellSpring is building a substantial portfolio of personal care items and OTC brands.”

On the market for over 65 years, Bactine® has been a favorite for generations, offering pain relief for first-aid injuries and an antiseptic that kills germs. It brings soothing skin protection for minor cuts, scrapes and burns.

Bactine,® is an excellent addition to the rapidly expanding personal care and OTC brand portfolio that WellSpring is building. Earlier this month, WellSpring announced its acquisition of FDS,® a leading feminine hygiene brand. Only about one year ago, the company acquired Bonine,® adding scale to its existing nausea franchise. Teaming with Emetrol,® WellSpring also markets Gelusil,® and Micatin,® along with a number of innovative personal care brands, including Glaxal Base,® skin moisturizers and Barriere™ silicone skin cream.

We are very excited about the acquisition of Bactine,” said Wendy Shusko, CEO at WellSpring. “We believe there is a great deal of potential in this iconic brand and look forward to leveraging its heritage in the first aid category. It is a fantastic product that relieves pain on contact and unlike many other first aid products, does not sting. It is an excellent addition to our growing portfolio. Its broad distribution in all major drug, mass and food retailers gives us an excellent platform to build upon with innovative new products and programs.”

The latest news about Ancor Capital Partners and our portfolio companies.